Find Academic Supervisors

• Inflammation Biology
• Cytokine Signaling
• Immunology
• +4 more

Professor Simon Jones is a distinguished academic at Cardiff University, serving as Dean of Research for the School of Medicine, Co-Director of the Systems Immunity Research Institute, and Research Theme Lead for Infection, Inflammation & Immunity. He is a Professor of Inflammation Biology with over 130 scientific publications and significant contributions to cytokine research. Dr. Jones earned his Ph.D. in Biochemistry from the University of Bristol (1990-1993) with supervisors Professor O.T.G. Jones and Dr. N. Topley, following his B.Sc. in Applied Biological Sciences (2.i Hons.) from Bristol Polytechnic (1986-1990). His academic journey includes prestigious fellowships at the University of Alabama at Birmingham (1996-1998) and the University of Bern, Switzerland (1994-1996). Professor Jones's research focuses on how cytokine signals shape inflammation, promote disease heterogeneity, and affect treatment outcomes. His work has made two major contributions: (1) identifying IL-6 trans-signalling as a determinant of disease progression, describing how interleukin-6 activities requiring the soluble IL-6 receptor promote communication between stromal tissues and recruited leukocytes; and (2) defining how IL-6 cytokines steer chronic disease, showing how the Jak-STAT pathway affects disease progression in rheumatoid arthritis and promotes treatment failure in renal patients on peritoneal dialysis. Analysis of Professor Jones's recent publications reveals a strong focus on IL-6 signaling pathways, their role in inflammation and disease progression, and potential therapeutic interventions. His work spans immunology, rheumatology, cardiology, and infectious disease, with particular emphasis on translational research connecting basic science to clinical applications. Recurring themes include cytokine signaling mechanisms, inflammation regulation, and development of targeted therapies for chronic inflammatory conditions. The 2004 Bolzmann Award (presented by the International Cytokine Society and the International Society for Interferon and Cytokine Research) Fellow of The Royal Society of Biology (June 2015) Fellow of the Learned Society of Wales Member of the Academia Europaea Professor Jones has served on numerous grant panels including the Royal Irish Academy Early Entry Grant Panel, Arthritis Research UK committees, and Health & Care Research Wales committees. He has advised multiple PhD students and has been involved in significant research collaborations with pharmaceutical companies including Roche, Genentech, Glaxo-Smith-Kline, and Johnson & Johnson. His leadership roles include chairing the REF Planning Committee and serving on the Wellcome Trust ISSF Board. Professor Jones leads research within the Systems Immunity Research Institute and the Cardiff Regional Experimental Arthritis Treatment Centre. His work involves multiple research teams focusing on inflammation biology, cytokine signaling, and translational immunology. He also serves on the Governance Committee for the Human Tissue Bank (Kidney) and is active in the Arthritis Research UK Centre of Excellence.

Przemysław ZarębaView profile

Assistant Professor

• Cancer pharmacotherapy
• Central nervous system diseases
• Bioactive compound design
• +7 more

Dr. Przemysław Zaręba is a Research and Teaching Assistant Professor at the Department of Chemical Technology and Environmental Analytics within the Faculty of Chemical Engineering and Technology at Tadeusz Kościuszko Cracow University of Technology. He holds a Doctor of Engineering degree (2023) and Master of Science in Engineering (2017), both from the same institution, specializing in Chemical Engineering and Light Organic Technology respectively. His research interests span cancer pharmacotherapy, central nervous system diseases, bioactive compound design, molecular modeling, and specifically focus on 5-HT receptor ligands and the PI3K/AKT/mTOR pathway for treating prostate cancer, glioblastoma, and other oncological conditions. Dr. Zaręba has developed expertise in designing dual-target inhibitors that simultaneously address multiple signaling pathways involved in cancer progression. Analysis of his recent publications reveals a strong focus on innovative therapeutic approaches targeting serotonin receptors (particularly 5-HT5A, 5-HT6, and 5-HT7) in various cancers, with emphasis on prostate cancer, glioblastoma, and triple-negative breast cancer. His work combines molecular modeling, organic synthesis using green chemistry principles, and comprehensive biological evaluation to develop novel therapeutic agents. Winner of the National Centre for Research and Development's LIDER program (14th edition, 2023) Recipient of the FNP Start scholarship (2023) Principal investigator for Proof of Concept grant (FNP, FENG perspective) Dr. Zaręba leads multiple significant research projects with substantial funding, including the LIDER14/0035/2023 project on 5-HT5A receptor ligands for castration-resistant prostate cancer (2024-2027), and collaborates with institutions like Nicolaus Copernicus University in Toruń on NCN Opus projects. His team includes researchers with complementary expertise in organic synthesis, pharmacological testing, and molecular modeling, creating a multidisciplinary approach to drug discovery.

Angela WaandersView profile

Associate Professor

• Neuro-Oncology
• Pediatric Brain Tumors
• Precision Medicine
• +3 more

Dr. Angela Waanders is an Associate Professor of Pediatrics specializing in Hematology, Oncology, and Stem Cell Transplantation at Northwestern University Feinberg School of Medicine. She serves as Section Head of Neuro-Oncology, Director of Precision Medicine Oncology, and Executive Board Chair of the Children's Brain Tumor Tissue Consortium at Ann & Robert H. Lurie Children's Hospital of Chicago. As Gus Foundation Chair in Neuro-Oncology, she leads groundbreaking research in pediatric brain tumors and precision medicine approaches. Dr. Waanders completed her medical education at Tulane University School of Medicine in 2003, followed by residency in pediatrics at Children's Hospital of Philadelphia (2003-2006), and fellowship in pediatric hematology/oncology at the same institution (2006-2009). She is board certified in Pediatrics and Pediatric Hematology-Oncology. Dr. Waanders' research focuses on advancing precision medicine for pediatric brain tumors, with particular expertise in molecular profiling of low-grade and high-grade gliomas. Her work investigates targeted therapies against molecular alterations in the MAPK and PI3K/mTOR pathways, with emphasis on overcoming resistance mechanisms to single-agent therapies. She has pioneered research on BRAF and CRAF gene fusions in pediatric low-grade gliomas and their response to RAF inhibitors. Dr. Waanders' recent publications demonstrate a clear trajectory toward precision medicine applications in pediatric neuro-oncology. Her work spans from basic genomic characterization to clinical implementation of molecularly targeted therapies. A significant focus is on RAF inhibitors (particularly tovorafenib) for relapsed/refractory pediatric low-grade glioma, representing a major advancement in targeted therapy for these challenging tumors. Dr. Waanders has been awarded the prestigious Gus Foundation Chair in Neuro-Oncology, recognizing her leadership and contributions to the field. Her work with the Children's Brain Tumor Tissue Consortium has significantly advanced tissue banking and molecular characterization of pediatric brain tumors. As Executive Board Chair of the Children's Brain Tumor Tissue Consortium, Dr. Waanders oversees one of the largest repositories of pediatric brain tumor specimens globally, facilitating numerous collaborative research projects. She leads multiple clinical trials including the FIREFLY-1 trial investigating tovorafenib for pediatric low-grade glioma and has contributed to the development of large fusion gene panels for pediatric cancer diagnostics. Dr. Waanders directs the Precision Medicine Oncology program at Lurie Children's Hospital, which integrates genomic analysis with clinical care to develop individualized treatment plans for children with brain tumors. She is a key member of the Pacific Pediatric Neuro-Oncology Consortium (PNOC) and co-leads multiple international collaborative efforts focused on pediatric brain tumor research and treatment optimization.

• Psychiatry
• Psychopharmacology
• Neuroscience
• +5 more

Tinh N Luong serves as an Assistant Clinical Professor in the Department of Psychiatry and Biobehavioral Sciences at the University of California, Los Angeles (UCLA) School of Medicine. His academic career spans both molecular biology and clinical psychiatry, reflecting an interdisciplinary approach to understanding mental health disorders. Dr. Luong's research interests encompass a wide spectrum from molecular neuroscience to clinical psychiatry. His early work focused on protein interactions, enzyme inhibitors, and molecular modeling, while his more recent publications address PTSD therapeutics, child mental health, and transcultural psychiatry. This trajectory demonstrates a movement from basic science toward clinical applications in mental health. Analysis of his publication history reveals a strong focus on the intersection of neuroscience and clinical psychiatry, particularly in understanding the molecular basis of mental illness and developing targeted therapeutic approaches. His work spans computational biology, molecular neuroscience, and clinical psychiatry applications. Dr. Luong has collaborated with researchers across multiple institutions including UCLA, UCSF, and UCI, working with notable scientists in both computational biology and clinical psychiatry fields. His research has been cited across various platforms with significant readership on academic networks.

• Virology
• Hepatitis C Research
• Molecular Cardiology
• +4 more

Elias Honerød Augestad is an Assistant Professor at the University of Copenhagen's Faculty of Health and Medical Sciences, Department of Biomedical Sciences, specializing in Molecular Cardiology and Membrane Proteins research. His work is centered at the Blegdamsvej 3B campus in Copenhagen, Denmark, where he conducts cutting-edge research on hepatitis C virus (HCV) molecular biology and immunology. Dr. Augestad's research primarily focuses on hepatitis C virus envelope proteins, particularly examining their structural organization, dynamics, and interactions with neutralizing antibodies. His work investigates how HCV evades immune responses through mechanisms like hypervariable region 1 modifications and how these insights can inform vaccine development. His laboratory employs advanced techniques including structural biology, virology, and immunology approaches to study viral entry mechanisms, antibody neutralization, and viral escape pathways. The research has significant implications for developing effective HCV vaccines that can overcome viral diversity and immune evasion strategies. Analysis of Dr. Augestad's publication record reveals a strong emphasis on translational virology research with direct applications to vaccine development. His work spans structural characterization of viral envelope complexes, identification of neutralizing antibody targets, evaluation of vaccine candidates, and investigation of viral escape mechanisms. The publications demonstrate collaborative work with leading HCV researchers including Bukh, Prentoe, and Gottwein, indicating participation in a well-established research network focused on hepatitis C. Dr. Augestad's research group appears to be actively engaged in both basic and applied aspects of HCV research, with publications appearing in high-impact journals including Nature, Hepatology, Journal of Hepatology, and Immunity. The work has generated significant attention in the scientific community, with multiple publications being highlighted by news outlets and widely shared on academic social media platforms.

• Membrane remodeling
• Immune receptor signaling
• Biomolecular condensation
• +7 more

Xiaolei Su is an Associate Professor of Cell Biology at Yale School of Medicine, with additional appointments in Biochemistry, Quantitative Biology, Biophysics and Structural Biology (BQBS), Cancer Immunology, and Molecular Cell Biology, Genetics and Development. He is affiliated with Yale Cancer Center, Yale Center for Immuno-Oncology, and Yale Center for Systems and Engineering Immunology (CSEI). Dr. Su received his BS in Biological Sciences from Peking University (2006), PhD in Cell and Developmental Biology from Harvard University (2012), and completed his postdoctoral training at UCSF under Ron Vale (2017). The Su Lab investigates the role of biomolecular condensation in immune response and leverages this knowledge for the development of novel cell therapies. Their research focuses on membrane remodeling and membrane receptor signaling during T cell and mast cell-mediated immune responses. They combine biochemical reconstitution with live cell imaging and animal models to understand how biomolecular condensation regulates immune signaling, with particular emphasis on CAR-T cell activation mechanisms. The lab has made significant contributions to understanding the size-dependent mechanism of CAR activation and how phase separation affects immune signaling. The lab has published extensively in high-impact journals including Nature Chemical Biology, Science Immunology, Journal of Cell Biology, and Nature Cancer. Their research shows a strong trend toward understanding the biophysical principles of immune cell signaling and applying these insights to improve cancer immunotherapies, particularly CAR-T cell therapies for solid tumors. Dr. Su has received numerous prestigious awards including: NIH Director's Transformative Award (2024) Lion Heart Pilot Award (2024) Pershing Square Sohn Prize for Young Investigators in Cancer Research (2023) Gabrielle's Angel Foundation Medical Research Award (2023) American Cancer Society Research Scholar Grant (2022) Dr. Su's research program is well-funded through multiple NIH and foundation grants. His work bridges fundamental discoveries in immune cell signaling with translational applications, particularly in designing new CARs and engineering immune cells to improve antitumor responses against blood, skin, colon, breast, ovarian, and brain cancers. The Su Lab maintains state-of-the-art facilities for live cell imaging, biochemical reconstitution, and animal modeling of cancer immunotherapies. The lab is part of Yale's vibrant immunology and cancer research ecosystem, with strong connections to Yale Cancer Center and multiple collaborative initiatives focused on advancing cancer immunotherapy.

• Hematopathology
• Oncologic Biomarkers
• Leukemia
• +5 more

Dr. Mina Xu is a Professor of Pathology and Laboratory Medicine at Yale School of Medicine, specializing in hematopathology and oncologic diagnostics. She directs Yale's Hematopathology division and Expert Consultation Practice, with affiliations spanning the Yale Cancer Center's genomics and immuno-oncology programs. Her research targets hematopoietic malignancies (leukemia, lymphoma, myeloma), biomarker discovery, and molecular diagnostics, utilizing cutting-edge techniques like spatial transcriptomics and AI-driven histopathology. Research Focus: Dr. Xu's work bridges tumor immunology, diagnostic innovation, and translational medicine. Key interests include: Development of immunohistochemical biomarkers for myeloid/lymphoid neoplasms Machine learning applications in predicting lymphoma transformation Spatial multi-omics mapping in archival tissue samples Therapeutic response prediction in targeted cancer therapies Recent Publications: Her 118+ articles (2023-2025) in journals like Nature Biotechnology and Blood demonstrate focus on: (1) Spatial transcriptomics for tumor microenvironments, (2) AI-enhanced diagnostic criteria, and (3) Novel biomarkers for hematologic malignancies. Trends show increasing integration of computational biology with clinical pathology. Awards & Honors: American Society of Hematology Trainee Grant (2005) Westinghouse Science Award (1996) National Science Foundation Trainee Grant (1994) Weizmann Institute of Science Scholarship (1996) Training & Collaboration: Actively mentors residents/fellows in pathology and collaborates with 13+ principal investigators, including Dr. Stephanie Halene (12 joint publications) and Dr. Amer Zeidan (9 joint publications). Research emphasizes team science within Yale Cancer Center consortia.